(Reuters) - The worldwide coronavirus death toll surpassed 2 million on Friday, according to a Reuters tally, as nations around the world are trying to procure multiple vaccines and detect new COVID-19 variants.
In the third in a series of conflicting announcements about a Chinese-made COVID-19 vaccine candidate, Brazilian researchers reported today that the results of their efficacy trial were less impressive than they claimed last week. When analyzed by stricter criteria than used earlier, the vaccine’s efficacy against all forms of COVID-19, including mild cases, dropped from about 78% to 50%.
The vaccine still appeared to give nearly 100% protection against disease severe enough to require hospitalization, although the trial amassed too few of those cases for that result to reach statistical significance.
Commenting at the press conference today, microbiologist Natália Pasternak Taschner, president of the Question of Science Institute, a Brazilian nonprofit that aims to support public policy based on scientific evidence, said it was a “clear and clean study” and stressed that she wants th vaccine for herself and her parents. “We do not need to say this is the best vaccine in the world,” said Pasternak, who was not involved with the trial. “We have to say that this is our vaccine and it is a good vaccine to start the process of pandemic control.”
